ARGS - Argos Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.11
+0.01 (+8.91%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close0.10
Open0.00
Bid2.39 x 900
Ask2.42 x 200
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume36,734
Market Cap1.165M
Beta1.53
PE Ratio (TTM)N/A
EPS (TTM)-2.53
Earnings DateMar 30, 2017 - Mar 31, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argos ...

  • ACCESSWIRE4 months ago

    Free Stock Performance Review on Array BioPharma and Three More Biotech Industry

    Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).

  • Argos discontinues troubled trial, delists from Nasdaq
    American City Business Journals5 months ago

    Argos discontinues troubled trial, delists from Nasdaq

    Argos made a series of announcements Thursday that reflect troubles stemming from a challenging 2017.

  • SmarterAnalyst5 months ago

    Here’s What’s Dragging Argos Therapeutics (ARGS) Stock Down Today

    Case in point: Argos Therapeutics (NASDAQ:ARGS) shares are tanking nearly 64% in Tuesday's trading session, after the drug maker reported disappointing interim results from its Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma. After consulting with the principal investigators of the trial, the Company has therefore decided to discontinue the trial. As previously reported, a total of 462 patients with previously untreated advanced or metastatic renal cell carcinoma were enrolled in the ADAPT trial and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm) after undergoing cytoreductive nephrectomy.

  • ACCESSWIRE5 months ago

    Blog Exposure - Alexion Pharma to Acquire Swedish Biotech Wilson Therapeutics

    Stock Monitor: Argos Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Trending Tickers: Argos Therapeutics and Bellicum Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 12, 2018 / U.S. markets fell sharply on Wednesday on growing geopolitical tensions. On Wednesday President Trump tweeted, "Russia vows to shoot down any and all missiles ...

  • Associated Press6 months ago

    Argos Therapeutics reports 4Q loss

    The Durham, North Carolina-based company said it had a loss of 38 cents per share. Losses, adjusted for non-recurring gains and to extinguish debt, came to $1.05 per share. The biotechnology company posted ...

  • Benzinga7 months ago

    A Day Trader's Guide To Fear

    To paraphrase an old love song: what a difference a week makes , and that difference is fear. I would be lying if the recent correction in the market didn’t catch me off guard. Since the rest of the market ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Trending Tickers: Argos Therapeutics and Sorrento Therapeutics

    NEW YORK, NY / ACCESSWIRE / February 7, 2017 / U.S. markets experienced a volatile day of trading Tuesday, but managed to snap the streak of two consecutive days of steep selloffs. The Dow Jones Industrial ...

  • Where Argos Therapeutics Inc (NASDAQ:ARGS) Stands In Terms Of Earnings Growth Against Its Industry
    Simply Wall St.8 months ago

    Where Argos Therapeutics Inc (NASDAQ:ARGS) Stands In Terms Of Earnings Growth Against Its Industry

    After reading Argos Therapeutics Inc’s (NASDAQ:ARGS) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past andRead More...

  • American City Business Journals8 months ago

    Heat latest Triangle biopharma to execute reverse stock split

    On the heels of Argos Therapeutics (ARGS) executing a one-for-twenty reverse stock split , another Durham-based biopharmaceutical company Heat Biologics (HTBX) has undertaken a one-for-ten reverse stock split of its own. Last year, Heat outlined a new strategy moving forward, focused on combination therapies for the treatment of cancer .

  • American City Business Journals8 months ago

    Argos executes reverse stock split

    Durham’s Argos Therapeutics (ARGS) has executed a one-for-twenty reverse stock split as well as a move from The Nasdaq Global Market to The Nasdaq Capital Market. Shares of Argos had remained under $1 for the better part of 2017, after a significant drop at the beginning of last year. The drop came in conjunction with an independent data monitoring committee’s recommendation that Argos discontinue its Phase 3 trial of lead product candidate Rocapuldencel-T – for the treatment of metastatic kidney cancer – sinking the company’s stock price more than 65 percent .

  • Should You Worry About Argos Therapeutics Inc’s (NASDAQ:ARGS) CEO Pay?
    Simply Wall St.9 months ago

    Should You Worry About Argos Therapeutics Inc’s (NASDAQ:ARGS) CEO Pay?

    Jeff Abbey has been at the helm as CEO of Argos Therapeutics Inc (NASDAQ:ARGS), which has grown to a market capitalization of $13.62M. Understanding how CEOs are incentivised to runRead More...

  • Capital Cube9 months ago

    ETFs with exposure to Argos Therapeutics, Inc. : December 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Argos Therapeutics, Inc. Here are 5 ETFs with the largest exposure to ARGS-US. Comparing the performance and risk of Argos Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • One Thing To Consider Before Buying Argos Therapeutics Inc (NASDAQ:ARGS)
    Simply Wall St.9 months ago

    One Thing To Consider Before Buying Argos Therapeutics Inc (NASDAQ:ARGS)

    If you are looking to invest in Argos Therapeutics Inc’s (NASDAQ:ARGS), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...